EMD and/or Bone Substitute for the Treatment of Class II Furcations

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To clinically evaluate the treatment of mandibular class II furcation defects with enamel matrix derivative (EMD) and/or a bone substitute graft make of beta tricalcium phosphate/hydroxyapatite (βTCP/HA).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Campinas, Brazil

Criteria

Inclusion Criteria:

• Males and females, between 18-75 years of age;

• Presence of a mandibular molar with buccal class-II furcation defect, presenting PD ≥ 4mm, bleeding on probing (BOP), minimum (<1 mm) or no gingival recession after non-surgical therapy;

• Good general health;

• Minimum interproximal bone loss (< 2 mm).

Exclusion Criteria:

• Pregnant or lactating;

• Required antibiotic pre-medication for the performance of periodontal examination and treatment;

• Suffered from any other systemic diseases (cardiovascular, pulmonary, liver, cerebral, diseases or diabetes);

• Had received antibiotic treatment in the previous 3 months;

• Were taking long-term anti-inflammatory drugs;

• Had received a course of periodontal treatment within the last 6 months;

• Smokers.